Despite encouraging clinical evidence, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is facing considerable opposition from pharmacy benefit managers. Such insurers are typically creating obstacles to coverage, including high expense restrictions and approval processes that restrict user opportunity.